Share
CNBC
Johnson & Johnson’s one-dose coronavirus vaccine is safe and appears to generate a promising immune response in both young and elderly volunteers, according to trial data published Wednesday in the New England Journal of Medicine.
J&J scientists randomly assigned healthy adults between the ages of 18 and 55 and those 65 and older to receive a high or low dose of its vaccine — called Ad26.COV2.S — or a placebo. Some participants in the 18-to-55 age group were also selected to receive a second dose of the vaccine.
Most of the volunteers produced detectable neutralizing antibodies, which researchers believe play an important role in defending cells against the virus, after 28 days, according to the trial data. By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-to-55 age group.
By Berkeley Lovelace Jr. | 13 Jan 2021
RELATED TOPICS:
Get a 3D First Look at Merced’s High-Speed Rail Station Design
2 hours ago
California Court to Decide on Transgender Ballot Measure Wording
2 hours ago
Rare House Vote Sees Ukraine, Israel Aid Advance as Democrats Join Republicans
4 hours ago
Full Jury and 6 Alternates Seated in Trump’s Hush Money Trial
4 hours ago
Logan Webb’s Seven Dominant Innings Help Giants Blank Diamondbacks
6 hours ago
Unlocking the Secrets to Fresno State’s Superb Baseball Season